A New Minimally Invasive Procedure for Muscle, Back, Neck Pain and Radiculopathy - The Myofascial Nerve Block

Omoigui S* and Fadare A

Department of Inflammation and Pain Research, LA Pain Clinic, USA

Abstract

This is the first description of a procedure targeting the myofascial tissues since Janet Travell’s description of myofascial trigger points in 1942. However unlike trigger point injections, this minimally invasive myofascial nerve injection is performed differently and targets the myofascial tissues, peripheral innervations, posterior spinal structures and spinal nerve roots at the same time. It is different from a trigger point injection that aims to block trigger points within a muscle. Prolonged standing or sitting, posture and other multiple factors can create recurrent injuries with attendant inflammation and episodically aggravate pain. Thus there is a need for a simple intervention technique that can be performed from the medical clinic to the battlefield to quickly relieve inflammation and prevent chronic pain.

Introduction

This myofascial nerve injection is also the first procedure for spine pain since epidural pain injection was first described by Jean-Anasthase Sicard in Paris on April 20th, 1901 [1,2]. However, at about the same time, Fernand Cathelin also from Paris had been treating patients with epidural injections for some months already [3].

Incidentally, a few months after we published our novel short needle technique for paraspinal muscle block in February 2016 [4,5], the Erector Spinae (ESP) nerve block was described in a publication in September 2016, as a regional block for thoracic neuropathic pain [6-8]. The injection is performed by a single shot or with a catheter insertion for continuous infusion (5 ml to 14 ml per hour) [9,10]. The primary mechanism is thought to be a direct effect of local anesthetic via physical spread and diffusion to the erector spinae muscles as well as neural structures in the fascial plane deep to the erector spinae muscles and adjacent tissue compartments [11]. Satisfactory results have been obtained in the treatment of both acute pain and chronic pain, and in some cases the ESP has replaced the use of epidural injections.

Clear solution of medication injected under pressure from a 30 G 5/8 inch (15.6 mm) needles travel a distance of 4 cm to 6 cm. As described in Sota Omoigui Short Needle Technique [4], utilizing the physics principle of the law of conservation of mass, the increased velocity of the injectate is sufficient to traverse the erector spinae muscles to the vertebral lamina and block the posterior spinal structures and nerves at the level injected [4]. Compressing the soft tissue with one hand, and injecting 1 ml to 2 ml Lidocaine 2% at the two most painful levels on each side of the vertebra or spinous process, we have been able to achieve 60% to 100% of relief of axial and radicular pain within 5 min. Total dosage of Lidocaine must be below the toxic dose of 3 mg/kg without epinephrine.

Due to the small size and length of the needle, this technique can be performed not just by pain specialist but by a primary care physician, physician assistant, nurse practitioner or any medical service provider trained to do intramuscular injections. This myofascial nerve block can be performed with or without imaging guidance in a variety of settings from the operating room to the medical clinic to the battlefield.

This myofascial nerve block may be used in combination with an anti-inflammatory regimen, including oral, IV or IM Steroid, Ketorolac/Diclofenac, Opioids, Ketamine, Ketorolac, Magnesium Sulfate, Kineret, CGRP Blockers, Botulinum Toxin etc. These block or inhibit various inflammatory mediators including prostaglandins (steroid, ketorolac/diclofenac), IL-1 Beta (Kineret) NMDA receptors (magnesium sulfate, ketamine), Substance P (Botulinum Toxin) etc [12].
Low back and neck pain causes more disability than any other and accounts for the third highest health care spending after diabetes and ischemic heart disease [13].

Subsequent to tissue injury, the initial immune reaction generates an inflammatory milieu of chemical mediators that include prostaglandin, interleukin 1-alpha, interleukin 1-beta, interleukin-4, Interleukin-6 and interleukin-8 nitric oxide, tumor necrosis factor alpha, histamine and serotonin [14,15].

Following this injury, there is increased nerve traffic in the sensory neurons that travel to the spinal cord and stimulate the release of inflammatory protein Substance P. The presence of Substance P and other inflammatory proteins such as Calcitonin Gene-Related Peptide (CGRP) neurokinin A and vasoactive intestinal peptide removes magnesium induced inhibition and enables excitatory inflammatory proteins such as glutamate and aspartate to activate specialized spinal cord NMDA receptors and increase magnification of the nerve traffic and pain stimuli.

Axial and radicular back pain is symptoms of injury that result in a cascade of inflammatory mediators. Local anesthetic agents stabilize nerve membrane and decrease pain by reducing the rate of discharge of sensory nerve fibers and decreasing neurogenic inflammation [16].

Current procedural injections for back, neck and radicular pain focus on structures that are visible with imaging, skeletal system (bones, joints, intervertebral discs) and central nervous system (brain and spinal cord) components while completely ignoring the largest organ in the spine and most often the initial site of injury, which are the paraspinal muscles–cervical, thoracic and lumbar. The most common pain procedures are essentially blind techniques as pain triggers are targeted based upon structural pathology. Unfortunately, there is poor correlation between structural pathology and the presence of back [17,18] or neck pain [19].

Myofascial tissues constitute a pain generator that is not addressed in current interventional pain procedures. Randomized controlled studies of current procedures have yielded conflicting results. In a study by Dilke et al., [20] patients who received epidural corticosteroids experienced less pain than controls, needed surgery less often and returned back to work sooner. However and on the contrary, Snoek et al., [21] showed that epidural steroid injection was no more effective than a placebo injection in relieving chronic symptoms due to lumbar disc herniation. In 2008, Staal et al. [22] reported on a systematic review of the literature conducted with a focus on randomized, controlled trials. Based on their analyses, the authors made the conclusion that there is moderate evidence that epidural corticosteroid injections are no more effective than placebo injections for pain relief.

Other procedures range from transforaminal injections, radiofrequency thermal lesioning of the medial branch nerves, radiofrequency cryolesioning of the medial branch nerves, intradiscal electrothermy (thermal burn to the intervertebral disc), and spinal cord stimulation. Recent randomized control trials have also questioned the effectiveness of these more invasive procedures. A multicenter, randomized, double-blind, sham treatment controlled trial was performed to determine the efficacy of radiofrequency lumbar facet joint denervation. In both groups, there was significant improvement in the Visual Analog Scale (VAS) [23]. In the Mint study, three randomized clinical trials were conducted on the effectiveness of minimal interventional treatments for participants with chronic low back pain. Radiofrequency denervation combined with a standardized exercise program resulted in either no improvement or no clinically important improvement in chronic low back pain compared with a standardized exercise program alone. In another randomized control trial, assessing the efficacy of Radiofrequency (RF) denervation of the cervical facet joints in chronic cervical facet joint pain the authors stated that they did not observe significant differences between RF denervation combined with injection of local anesthesia compared with local anesthesia at 6 months follow-up. The need for pain medication did not differ significantly between groups [24]. In another randomized controlled trial, in patients with cervicogenic headache the authors did not find evidence that radiofrequency treatment of cervical facet joints was a better treatment than the infiltration of the greater occipital nerve [25].

In one study the author stated that the evidence is poor for cervical transforaminal epidural injections. Complications with cervical interlaminar epidural injections are rare, but more commonly occur with transforaminal epidural injections. These can be fatal and include vertebral artery injury, systemic allergic reactions to radio contrast agents, transient cortical blindness and brain injury [26], stroke, paraplegia, quadriplegia, spinal cord and cerebellar infarction [27,28].

These trials raise the issue of questionable benefits, compared to simpler procedures such as our myofascial nerve blockade.

As stated in the NIH, HEAL Initiative Fund Opportunity [29], the field of musculoskeletal pain has largely focused on the skeletal system (bones, joints, intervertebral discs) and central nervous system (brain and spinal cord) components. The contribution of myofascial tissues, especially fascia, and the interactions of fascia, muscles, and peripheral nerves are understudied and remain mostly unknown. Pain originating from muscles and fascia is likely an important component of many severe and chronic pain conditions. The perimuscular fascia is richly innervated with small-diameter fibers whose receptive fields increase in the presence of inflammation. Thus myofascial tissues play a significant role as pain generators.

The NIH noted that for many years, structural imaging was the main tool to guide treatment decisions, including surgery. Meanwhile, imaging and other objective measurements of “soft” tissues including muscles, and connective tissues or “fasciae,” were not even considered as musculoskeletal pain biomarker candidates. Thus NIH has called for development of biomarkers of myofascial tissues for effective pain management regimens.

In the last seven years, we have replaced epidural and facet joint/nerve injections with a myofascial nerve block. We routinely perform myofascial nerve injections, with or without ultrasound guidance to relieve pain. We had observed during spinal procedures that a clear solution of Lidocaine 2%, injected from a 30G 5/8 inch (15.6 mm) needle, using a 3 ml syringe, and inserted just lateral to the spinous process, into the paraspinal muscles, traveled a distance of 4cm to 6 cm [4]. This distance was sufficient to travel through the erector spinae muscles down to the vertebral lamina and posterior spinal structures and within minutes produce anesthetic block to relieve radicular pain from the nerve roots [4].

In the last two years, the advent of erector spinae plane blocks that are essentially myofascial blocks but utilizing longer needles inserted to the target point, with large volumes of dilute local anesthetic has validated our original but simpler myofascial nerve block (Figures 1-6).
Discussion

When a 30 gauge needle is attached to a 3 ml syringe, the distance of travel of medication from the syringe and needle into tissue will be greater, because there is increased velocity through the smaller needle and hence greater penetration of medication into the tissues.

Utilizing the equation of continuity, we can analyze what happens to the fluid if the size of the tubing through which it flows, changes. Figure 7 shows the pipe constricting from area A₁ to area A₂. Since no fluid can leave through the walls, the mass crossing each section of the tube per unit time must be the same. Therefore the velocity of fluid through the smaller area is faster than the velocity of the fluid through the larger area. This phenomenon can be explained and quantified by examining the flow rate of mass through the tubing. The equation of continuity states that, in any steady state process, the rate at which mass enters a system is equal to the rate at which mass leaves the system:
Flow rate through \( A_1 \) = Flow rate through \( A_2 \)
\[ d_1A_1v_1 = d_2A_2v_2 \]
Therefore,
\[ dAv = \text{Constant} \]

This equation expresses the law of conservation of mass in fluid dynamics.

If fluid is incompressible, then the density is constant \( (d_1 = d_2) \).

Then,
\[ A_1v_1 = A_2v_2 \]
Where
\[
\begin{align*}
A_1 &= \text{Area in tube 1} \\
v_1 &= \text{Velocity in tube 1} \\
A_2 &= \text{Area in tube 2} \\
v_2 &= \text{Velocity in tube 2} \\
d &= \text{density of the fluid}
\end{align*}
\]

For our purpose, \( A_1v_1 \) will be a syringe and \( A_2v_2 \) the hypodermic needle. When a higher gauge (smaller) needle is used, with a 3 ml syringe, the distance of travel of medication from the syringe and needle into tissue will be greater, because there is increased velocity through the smaller needle and hence greater penetration of medication into the tissues.

**Advantages**

Clear fluid medications can be injected to traverse and provide a therapeutic effect at a distance to the needle point e.g. paraspinal muscles and lamina.

**Limitations**

This targeted structure must be within 6 cm distance and not obstructed by bone e.g. a hip or knee joint.

**Myofascial Injection Technique**

With the Myofascial Injection Technique for Spinal Pain, the spine is palpated to locate the most painful sites. A short 30G 5/8 inch needle is inserted adjacent to the spinal process or vertebral at the level of those sites. The soft tissue is compressed and the needle is advanced just past the subcutaneous tissue into the muscle layer, and 1 ml to 2 ml of local anesthetic solution (preferably 2% Lidocaine for most sites) is injected in each site. If performed under ultrasound guidance the solution will be seen to spread 4 cm to 6 cm deep into the paraspinous muscle, down to the lamina and posterior spinal structures. The injection is repeated at the 2 to 4 most painful sites, keeping in mind not to exceed the toxic dose of the local anesthetic (3 mg/kg). The number of sites injected is limited by the volume and concentration of local anesthetic injected so as not to exceed the toxic dose of anesthetic.

With the myofascial injection, the soft tissue is compressed and the needle is inserted close to its hub (5/8 in), the medication is injected to reach the target site. In most instances, it is no longer necessary to use longer and bigger gauge needles for epidural injections for treatment of axial pain and radiculopathy. With a myofascial injection, the medication can be pushed under pressure through the erector spinae muscle to block the posterior spinal structures, using a smaller shorter needle. Use of such a short small bore needle such as the BD 30G 5/8 inch needle will make myofascial injections much safer as there is significantly decreased risk of needle trauma. This technique is also useful in patients who are anti-coagulated. Compression of the skin and subcutaneous fatty tissue reduces the distance of travel required for the medication to penetrate through the paraspinous muscle to the posterior spinal structures.

**Distances**

Clear solution of medication injected under pressure from a 30G 5/8 inch (15.6 mm) needles travel a distance of 4 cm to 6 cm.

In the lumbar spine, the distance from the skin to the ligamentum flavum is 3 cm to 8 cm [30-32]. In the upper thoracic spine the distance from skin to the lamina with a paramedian approach, 1 cm from the midline, is 4.2 cm, middle thoracic spine is 3.7 cm, lower thoracic spine is 3.6 cm and lumbar spine is 4.0 cm. The average distance from skin to the epidural space with a paramedian approach, 1 cm from the midline, in the upper thoracic spine is 5.6 cm, middle thoracic spine is 5.2 cm, lower thoracic spine is 4.4 cm and lumbar spine is 4.7 cm [33]. The mean distance from the skin to the transverse processes and facet joint articular processes, ranges from 3.2 cm to 5 cm, as measured in a study utilizing a 3 MHz to 5 MHz ultrasound probe see Figure 8 [34].

We have had a variable duration of pain relief from one week to one year and similar to the epidural steroid and facet nerve injections.
that we previously performed. There have been no complications with this technique, in more than 500 procedures.

Conclusion

The Myofascial nerve injection is a simple intervention technique that can be performed from the medical clinic to the battlefield to quickly relieve inflammation, treat acute pain and prevent chronic pain.

It is the first procedure that targets the myofascial tissues, peripheral innervations, posterior spinal structures and spinal nerve roots at the same time.

Due to the small size and length of the needle, this technique can be performed not just by pain specialist but by a primary care physician, physician assistant, nurse practitioner or any medical service provider trained to do intramuscular injections.

The therapeutic and anti-inflammatory effect of the myofascial nerve injection is from the neuro-modulatory activity local anesthetic (preferably 2% Lidocaine for most injection sites). The myofascial injection procedure using the Sota Omoigui Short Needle Technique may be combined with an anti-inflammatory regimen that may be administered by the parenteral route.

Funding

This publication was made possible by a grant from the National Institute of Health: F32 AR008429-01/AR/NIAMS NIH HHS.

Video 1: Video of ultrasound during myofascial injection procedure.

References

5. Omoigui S. Merging physics with anesthesia presented at the International Anesthesia Research Society Conference, May 16th, 2019, Montreal, Quebec, Canada.

32. Neuraxial Blockade Anatomy and Landmarks.
